This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Robbins Umeda LLP Announces An Investigation Of The Acquisition Of Abraxis BioScience Inc. By Celgene Corporation

Robbins Umeda LLP has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by members of the Board of Directors of Abraxis BioScience Inc. ("Abraxis" or the "Company") (NASDAQ:ABII) in connection with their actions in causing Abraxis to enter into a definitive merger agreement to be acquired by Celgene Corporation ("Celgene") (NASDAQ:CELG). If the transaction is completed, Abraxis shareholders will receive $58.00 in cash and 0.2617 shares of Celgene common stock for each share of Abraxis they hold, for an implied value of approximately $71.93 per Abraxis share. Each share will also receive one tradeable Contingent Value Right, which entitles its holder to receive payments for future regulatory milestones and commercial royalties. If approved, the transaction is expected to close in the fourth quarter of 2010.

Robbins Umeda LLP's investigation concerns whether the Board of Directors of Abraxis undertook a fair process to obtain fair consideration for all shareholders of Abraxis. Notably, Abraxis has developed a drug, Abraxane, which has shown very positive response rate data in non-small cell lung cancer. According to WedBush Securities analyst Michael King, Jr., Abraxane should generate nearly $400 million in revenue in 2010. This analyst also stated, "Abraxane has also shown intriguing activity in pancreatic cancer and melanoma, two very difficult to treat tumor types. Should these trials read out positively, Abraxane would open up important new markets for itself." Despite this promising drug, the Company's fiduciaries are attempting to sell Abraxis at a premium of only 17.32%.

If you are a shareholder of Abraxis, plan to continue to hold your shares, and would like more information about your rights as a shareholder, please contact attorney Gregory E. Del Gaizo at 800-350-6003 or by e-mail at info@robbinsumeda.com.

Robbins Umeda LLP is a California-based law firm with significant experience representing investors in merger-related shareholder class actions, shareholder derivative actions, and securities fraud class actions. For more information about the firm, please go to http://www.robbinsumeda.com.

Advertisement

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
CELG $131.25 0.00%
AAPL $121.30 0.00%
FB $94.01 0.00%
GOOG $625.61 0.00%
TSLA $266.15 0.00%

Markets

Chart of I:DJI
DOW 17,689.86 -56.12 -0.32%
S&P 500 2,103.84 -4.79 -0.23%
NASDAQ 5,128.2810 -0.5040 -0.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs